StockGlow

BioCryst Pharmaceuticals, Inc. (BO1.F)

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases.

8.03-0.02%Healthcare
Compare BO1.F with
StockGlow Score
79
Leaning Bullish
BearishBullish
1 year ago+14.6%

The outlook

BioCryst Pharmaceuticals, Inc. currently reads as leaning bullish based on above its 50- & 200-day averages, 57% of the way from its 52-week low to high. This is a snapshot of current market data, not a forecast.

What’s behind the score

Price trendAbove its 50- & 200-day averages
52-week range57% of the way from its 52-week low to high
Market cap
$2.04B
52-wk high
10.19
52-wk low
5.18
50-day avg
7.99
200-day avg
7.04
Trailing P/E
—

Similar stocks

NVV1.FNovavax, Inc.$6.46-0.15%XS4.FON Semiconductor Corporation$74.75+1.89%GIS.FGilead Sciences, Inc.$113.82+0.51%2L9.FVisionWave Holdings, Inc.$1.63-3.66%AX9.FAkebia Therapeutics, Inc.$1.15+6.85%

The StockGlow Score is a snapshot of current, observable market data (analyst ratings, price trend, 52-week range) — not a prediction, forecast, or recommendation. Informational only, not investment advice. Data from public sources and may be delayed. How this works·Privacy